Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Quattro Financial Advisors LLC

Quattro Financial Advisors LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 576 shares of the medical research company’s stock after selling 23 shares during the period. Thermo Fisher Scientific comprises 0.0% of Quattro Financial Advisors LLC’s portfolio, making the stock its 7th biggest position. Quattro Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $300,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Thermo Fisher Scientific by 18.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 56,387 shares of the medical research company’s stock valued at $28,502,000 after purchasing an additional 8,722 shares during the last quarter. Osprey Private Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Osprey Private Wealth LLC now owns 9,380 shares of the medical research company’s stock valued at $4,880,000 after purchasing an additional 65 shares during the last quarter. Sargent Investment Group LLC grew its stake in shares of Thermo Fisher Scientific by 7.1% during the fourth quarter. Sargent Investment Group LLC now owns 711 shares of the medical research company’s stock valued at $395,000 after purchasing an additional 47 shares during the last quarter. Old North State Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 14.0% during the fourth quarter. Old North State Wealth Management LLC now owns 528 shares of the medical research company’s stock valued at $275,000 after purchasing an additional 65 shares during the last quarter. Finally, Ninety One SA PTY Ltd boosted its stake in Thermo Fisher Scientific by 4.6% in the fourth quarter. Ninety One SA PTY Ltd now owns 14,922 shares of the medical research company’s stock valued at $7,763,000 after acquiring an additional 653 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent research reports. TD Cowen raised their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Citigroup raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, Wells Fargo & Company lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Trading Down 2.2 %

Shares of NYSE:TMO opened at $580.63 on Wednesday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $542.95 and its 200 day simple moving average is $571.55. The firm has a market cap of $222.09 billion, a price-to-earnings ratio of 35.13, a PEG ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 9.44%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.